Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy

1481PDAPREPITANT FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING WITH A MODERATELY EMETOGENIC CHEMOTHERAPY: A MULTICENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY IN JAPANESE GYNECOLOGIC PATIENTS RECEIVING PACLITAXEL AND CARBOPLATIN

(2017) H. Yahata et al.   ANNALS OF ONCOLOGY

A prospective study on the incidence of delayed nausea and vomiting following administration of carboplatin containing regimens for treatment of cancer without prophylactic aprepitant

(2017) M. A. Waqar et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial

(2015) C. Weinstein et al.   ANNALS OF ONCOLOGY

Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review

(2015) K. Jordan et al.   ANNALS OF ONCOLOGY

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial

(2015) Lee S Schwartzberg et al.   LANCET ONCOLOGY

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials

(2015) Bernardo L Rapoport et al.   LANCET ONCOLOGY

Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer

(2015) Hideki Kusagaya et al.   LUNG CANCER

Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy

(2014) Yasuhiro Ito et al.   LUNG CANCER

A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy

(2013) M Tanioka et al.   BRITISH JOURNAL OF CANCER

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

(2011) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

(2010) F. Roila et al.   ANNALS OF ONCOLOGY

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

(2009) Bernardo L. Rapoport et al.   SUPPORTIVE CARE IN CANCER

Chemotherapy-Induced Nausea and Vomiting

(2008) Paul J. Hesketh   NEW ENGLAND JOURNAL OF MEDICINE